# US 2021/0069174 A1 · Compositions and methods for treatment of cystic fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069174 A1
- Document ID: US20210069174A1
- Status: Published application
- Kind: A1
- Application number: 16/625,028
- Filed: 2018-06-29
- Published: 2021-03-11
- Earliest claimed: 2017-07-01
- Assignees: Vertex Pharmaceuticals Incorporated
- Applicants: Vertex Pharmaceuticals Incorporated
- Inventors: Cathy Chu; Eleni Dokou; Eric L. Haseltine; Samuel Moskowitz; Kirk A. Overhoff; Sarah Robertson; David Waltz
- Web page: https://patentgrep.com/patent/US20210069174A1

## CPC

- A61K 31/47: Quinolines; Isoquinolines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2095: {Tabletting processes}
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions comprising Compound I of the formula (I) and methods of treating cystic fibrosis comprising administering Compound I. Compositions comprising a pharmaceutically acceptable salt of Compound I and methods of treating cystic fibrosis comprising administering a pharmaceutically acceptable salt of Compound I.

## Claims

### Claim 1

A method of treating cystic fibrosis comprising administering to a patient in need thereof:
(A) 400 mg to 1600 mg of at least one compound chosen from Compound I:
and pharmaceutically acceptable salts thereof daily; and
(B) 25 mg to 200 mg of at least one compound chosen from Compound II:
and pharmaceutically acceptable salts thereof daily; and
(C) 50 mg to 800 mg of at least one compound chosen from Compound III:
and pharmaceutically acceptable salts thereof daily.

### Claim at position 2

-33. (canceled)

### Claim 34 (depends on 1)

The method of claim 1, wherein the Compound I or pharmaceutically acceptable salts thereof, Compound II or pharmaceutically acceptable salts thereof, and Compound III or pharmaceutically acceptable salts thereof, are administered in a pharmaceutical composition comprising:
(A) 200 mg to 1600 mg of at least one compound chosen from Compound and pharmaceutically acceptable salts thereof;
(B) 25 mg to 200 mg of at least one compound chosen from Compound
and pharmaceutically acceptable salts thereof;
(C) 50 mg to 800 mg of at least one compound chosen from Compound
and pharmaceutically acceptable salts thereof; and
(D) a pharmaceutically acceptable carrier.

### Claim at position 4

-65. (canceled)

### Claim 66 (depends on 1)

The method of claim 1, wherein:
(A) the Compound I or pharmaceutically acceptable salts thereof is administered in a first pharmaceutical composition comprising 200 mg to 1600 mg of at least one compound chosen from Compound I and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier; and
(B) the Compound II, or pharmaceutically acceptable salts thereof, and the Compound III, or pharmaceutically acceptable salts thereof are administered in a second pharmaceutical composition comprising: (i) 25 mg to 200 mg of at least one compound chosen from Compound II
and pharmaceutically acceptable salts thereof (ii) 50 mg to 800 mg of at least one compound chosen from Compound III
and pharmaceutically acceptable salts thereof, and (iii) a pharmaceutically acceptable carrier.

### Claim at position 6

-127. (canceled)

### Claim 128

A single tablet comprising a first solid dispersion, a second solid dispersion, and a third solid dispersion,
(a) wherein the first solid dispersion comprises 50 mg to 800 mg of Compound I:
and 10 wt % to 60 wt % of a polymer relative to the total weight of the first solid dispersion;
(b) wherein the second solid dispersion comprises 3 mg to 70 mg of Compound II:
and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion; and
(c) wherein the third solid dispersion comprises 10 mg to 400 mg of Compound
and 10 wt % to 30 wt % of a polymer relative to the total weight of the third solid dispersion.

### Claim at position 8

-164. (canceled)

### Claim 165 (depends on 128)

The single tablet of claim 128, wherein the tablet comprises:
(a) 30 wt % to 50 wt % of the first solid dispersion comprising Compound I relative to the total weight of the tablet;
(b) 1 wt % to 8 wt % of the second solid dispersion comprising Compound II relative to the total weight of the tablet; and
(c) 10 wt % to 35 wt % of the third solid dispersion comprising Compound III relative to the total weight of the tablet;
wherein the first solid dispersion comprises 40 wt % to 90 wt % of Compound I and 10 wt % to 60 wt % of a polymer relative to the total weight of the first solid dispersion;
wherein the second solid dispersion comprises 70 wt % to 90 wt % of Compound II
and 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion; and
wherein the third solid dispersion comprises 70 wt % to 90 wt % of Compound III
and 10 wt % to 30 wt % of a polymer relative to the total weight of the third solid dispersion.

### Claim at position 10

-196. (canceled)

### Claim 197

A single tablet comprising a solid dispersion comprising 50 mg to 800 mg of Compound I:
3 mg to 70 mg of Compound II:
10 mg to 400 mg of Compound III:
and
one or more polymers.

### Claim at position 12

-256. (canceled)

### Claim 257 (depends on 128)

A method of treating cystic fibrosis in a patient comprising orally administering to the patient the single tablet of claim 128.

### Claim at position 14

-265. (canceled)

### Claim 266

A pharmaceutical composition comprising a solid dispersion comprising: (a) Compound I
and (b) a polymer; and
a pharmaceutically acceptable carrier.

### Claim at position 16

-284. (canceled)

### Claim 285 (depends on 1)

The method of claim 1, wherein the method comprises administering:
(A) 200 mg of at least one compound chosen from Compound I and pharmaceutically acceptable salts thereof twice daily
(B) 100 mg of at least one compound chosen from Compound II and pharmaceutically acceptable salts thereof once daily
and
(C) 150 mg of at least one compound chosen from Compound III and pharmaceutically acceptable salts thereof twice daily

### Claim 286 (depends on 1)

The method of claim 1, wherein the method comprises administering:
(A) 200 mg of at least one compound chosen from Compound I and pharmaceutically acceptable salts thereof twice daily
(B) 50 mg of at least one compound chosen from Compound II and pharmaceutically acceptable salts thereof twice daily
and
(C) 150 mg of at least one compound chosen from Compound III and pharmaceutically acceptable salts thereof twice daily

### Claim 287 (depends on 1)

The method of claim 1, wherein the method comprises administering:
(A) 600 mg of at least one compound chosen from Compound I and pharmaceutically acceptable salts thereof twice daily
(B) 50 mg of at least one compound chosen from Compound II and pharmaceutically acceptable salts thereof twice daily
and
(C) 300 mg of at least one compound chosen from Compound III and pharmaceutically acceptable salts thereof twice daily

### Claim at position 20

-318. (canceled)
